Proflamin, a new antitumor agent: preparation, physicochemical properties and antitumor activity.
Proflamin is a new biological response-modifying antitumor agent. It was isolated from the culture mycelium of Flammulina velutipes (Curt. ex Fr.) Sing. by means of ion exchange column chromatography and molecular sieving. It is a weakly acidic glycoprotein containing more than 90% protein and less than 10% carbohydrate, and its molecular weight is 13,000 +/- 4,000. The antitumor effect of proflamin was studied with murine tumors. It was markedly effective against the syngeneic tumors, B-16 melanoma (B-16) and adenocarcinoma 755 (Ca-755). At a dose of 10 mg/kg po, the increases in median survival time of mice with B-16 and Ca-755 were 86 and 84%, respectively. Proflamin exhibited no cytocidal effect against the cultured cell lines in vitro. Oral administration of proflamin produced no lethal or any other apparent adverse effect in mice.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000284:Administration, Oral; D000363:Agaricales / Q000032:analysis; D000818:Animals; D002460:Cell Line; D004591:Electrophoresis, Polyacrylamide Gel; D005656:Fungal Proteins; D006023:Glycoproteins / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins; D007939:Leukemia L1210 / Q000188:drug therapy / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology*; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology
D005656:Fungal Proteins; D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; C044645:proflamin protein, Flammulina velutipes